{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:43:31Z","timestamp":1786995811336,"version":"build-2736575974"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["J3\\u20132535"],"award-info":[{"award-number":["J3\\u20132535"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Lipid Research"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.plipres.2024.101302","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T18:58:48Z","timestamp":1728673128000},"page":"101302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["From fallopian tube epithelium to high-grade serous ovarian cancer: A single-cell resolution review of sex steroid hormone signaling"],"prefix":"10.1016","volume":"96","author":[{"given":"Marija","family":"Gjorgoska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tea Lani\u0161nik","family":"Ri\u017ener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.plipres.2024.101302_bb0005","series-title":"Global cancer observatory: Cancer today","author":"Ferlay","year":"2024"},{"key":"10.1016\/j.plipres.2024.101302_bb0010","doi-asserted-by":"crossref","first-page":"16061","DOI":"10.1038\/nrdp.2016.61","article-title":"Ovarian cancer","volume":"2","author":"Matulonis","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.plipres.2024.101302_bb0015","series-title":"Female genital tumours\u202f: WHO classification of tumours","volume":"Volume 4","year":"2020"},{"issue":"11","key":"10.1016\/j.plipres.2024.101302_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10110433","article-title":"Cell origins of high-grade serous ovarian cancer","volume":"10","author":"Kim","year":"2018","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.plipres.2024.101302_bb0025","doi-asserted-by":"crossref","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","article-title":"Epidemiology of ovarian cancer: a review","volume":"14","author":"Reid","year":"2017","journal-title":"Cancer Biol Med"},{"issue":"3","key":"10.1016\/j.plipres.2024.101302_bb0030","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","article-title":"ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease","volume":"35","author":"Ledermann","year":"2024","journal-title":"Ann Oncol"},{"issue":"26","key":"10.1016\/j.plipres.2024.101302_bb0035","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.plipres.2024.101302_bb0040","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41571-023-00819-1","article-title":"Heterogeneity and treatment landscape of ovarian carcinoma","volume":"20","author":"Veneziani","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"7353","key":"10.1016\/j.plipres.2024.101302_bb0045","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Bell","year":"2011","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.plipres.2024.101302_bb0050","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discov"},{"issue":"16","key":"10.1016\/j.plipres.2024.101302_bb0055","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","article-title":"Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome","volume":"14","author":"Tothill","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.plipres.2024.101302_bb0060","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1158\/1078-0432.CCR-18-0784","article-title":"Consensus on molecular subtypes of high-grade serous ovarian carcinoma","volume":"24","author":"Chen","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.plipres.2024.101302_bb0065","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/PAS.0000000000000353","article-title":"Incidental nonuterine high-grade serous carcinomas arise in the fallopian tube in most cases: further evidence for the tubal origin of high-grade serous carcinomas. Article","volume":"39","author":"Gilks","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.plipres.2024.101302_bb0070","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41467-017-00962-1","article-title":"High grade serous ovarian carcinomas originate in the fallopian tube","volume":"8","author":"Labidi-Galy","year":"2017","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.plipres.2024.101302_bb0075","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/01.pas.0000213335.40358.47","article-title":"Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship","volume":"31","author":"Kindelberger","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.plipres.2024.101302_bb0080","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ccell.2020.01.003","article-title":"The repertoire of serous ovarian cancer non-genetic heterogeneity revealed by single-cell sequencing of normal fallopian tube epithelial cells","volume":"37","author":"Hu","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.plipres.2024.101302_bb0085","series-title":"Practical gynecologic pathology: Frequently asked questions","first-page":"193","article-title":"Diseases of the fallopian tube","author":"Xing","year":"2021"},{"issue":"1","key":"10.1016\/j.plipres.2024.101302_bb0090","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/path.2091","article-title":"A candidate precursor to serous carcinoma that originates in the distal fallopian tube","volume":"211","author":"Lee","year":"2007","journal-title":"J Pathol"},{"issue":"2","key":"10.1016\/j.plipres.2024.101302_bb0095","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.pas.0000180854.28831.77","article-title":"The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome","volume":"30","author":"Medeiros","year":"2006","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.plipres.2024.101302_bb0100","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/path.5219","article-title":"Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions","volume":"248","author":"Wu","year":"2019","journal-title":"J Pathol"},{"issue":"1","key":"10.1016\/j.plipres.2024.101302_bb0105","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41379-019-0370-1","article-title":"Natural history of ovarian high-grade serous carcinoma from time effects of ovulation inhibition and progesterone clearance of p53-defective lesions","volume":"33","author":"Wu","year":"2020","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.plipres.2024.101302_bb0110","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1086\/318787","article-title":"Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer","volume":"68","author":"Risch","year":"2001","journal-title":"Am J Hum Genet"},{"issue":"4","key":"10.1016\/j.plipres.2024.101302_bb0115","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited mutations in women with ovarian carcinoma","volume":"2","author":"Norquist","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.plipres.2024.101302_bb0120","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2147\/IJWH.S197604","article-title":"Ovarian cancer in the world: epidemiology and risk factors","volume":"11","author":"Momenimovahed","year":"2019","journal-title":"Int J Womens Health"},{"issue":"3","key":"10.1016\/j.plipres.2024.101302_bb0125","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.ygyno.2022.04.001","article-title":"Lifetime ovulations and epithelial ovarian cancer risk and survival: a systematic review and meta-analysis","volume":"165","author":"Fu","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.plipres.2024.101302_bb0130","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S0015-0282(16)48496-7","article-title":"Cyclic changes in ciliation, cell height, and mitotic activity in human tubal epithelium during reproductive life","volume":"43","author":"Donnez","year":"1985","journal-title":"Fertil Steril"},{"issue":"5","key":"10.1016\/j.plipres.2024.101302_bb0135","doi-asserted-by":"crossref","DOI":"10.1093\/molehr\/gaad012","article-title":"Cyclic processes in the uterine tubes, endometrium, myometrium, and cervix: pathways and perturbations","volume":"29","author":"Holdsworth-Carson","year":"2023","journal-title":"Mol Hum Reprod"},{"issue":"2","key":"10.1016\/j.plipres.2024.101302_bb0140","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/ijc.31063","article-title":"Histological subtypes of ovarian cancer associated with parity and breastfeeding in the prospective million women study","volume":"142","author":"Gaitskell","year":"2018","journal-title":"Int J Cancer"},{"issue":"5645","key":"10.1016\/j.plipres.2024.101302_bb0145","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"issue":"23","key":"10.1016\/j.plipres.2024.101302_bb0150","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.plipres.2024.101302_bb0155","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrc3181","article-title":"BRCA1 and BRCA2: different roles in a common pathway of genome protection","volume":"12","author":"Roy","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.plipres.2024.101302_bb0160","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/1055-9965.EPI-11-0775","article-title":"Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1\/2 (CIMBA)","volume":"21","author":"Mavaddat","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"5","key":"10.1016\/j.plipres.2024.101302_bb0165","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMra1503523","article-title":"The role of risk-reducing surgery in hereditary breast and ovarian cancer","volume":"374","author":"Hartmann","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.plipres.2024.101302_bb0170","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/S1470-2045(13)70448-0","article-title":"The sex hormone system in carriers of BRCA1\/2 mutations: a case-control study","volume":"14","author":"Widschwendter","year":"2013","journal-title":"Lancet Oncol"},{"issue":"9574","key":"10.1016\/j.plipres.2024.101302_bb0175","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/S0140-6736(07)60534-0","article-title":"Ovarian cancer and hormone replacement therapy in the million women study","volume":"369","author":"Beral","year":"2007","journal-title":"The Lancet"},{"key":"10.1016\/j.plipres.2024.101302_bb0180","article-title":"Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study","volume":"362","author":"Iversen","year":"2018","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.plipres.2024.101302_bb0185","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s00432-021-03629-z","article-title":"Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review","volume":"147","author":"Huber","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"10.1016\/j.plipres.2024.101302_bb0190","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1056\/NEJM198703123161102","article-title":"The reduction in risk of ovarian cancer associated with oral-contraceptive use","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.plipres.2024.101302_bb0195","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13048-021-00911-z","article-title":"Investigation on factors associated with ovarian cancer: an umbrella review of systematic review and meta-analyses","volume":"14","author":"Tanha","year":"2021","journal-title":"J Ovarian Res"},{"issue":"9609","key":"10.1016\/j.plipres.2024.101302_bb0200","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(08)60167-1","article-title":"Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23257 women with ovarian cancer and 87303 controls","volume":"371","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.plipres.2024.101302_bb0205","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1158\/1055-9965.EPI-15-1272-T","article-title":"Circulating estrogens and postmenopausal ovarian cancer risk in the Women\u2019s Health Initiative observational study","volume":"25","author":"Trabert","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"8","key":"10.1016\/j.plipres.2024.101302_bb0210","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1002\/ijc.32157","article-title":"Circulating androgens and postmenopausal ovarian cancer risk in the Women\u2019s Health Initiative observational study","volume":"145","author":"Trabert","year":"2019","journal-title":"Int J Cancer"},{"issue":"14","key":"10.1016\/j.plipres.2024.101302_bb0215","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1158\/0008-5472.CAN-16-3322","article-title":"Androgens are differentially associated with ovarian cancer subtypes in the ovarian cancer cohort consortium","volume":"77","author":"Ose","year":"2017","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.plipres.2024.101302_bb0220","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s10552-019-01233-8","article-title":"Circulating estrogens and postmenopausal ovarian and endometrial cancer risk among current hormone users in the Women\u2019s Health Initiative observational study","volume":"30","author":"Trabert","year":"2019","journal-title":"Cancer Causes Control"},{"issue":"11","key":"10.1016\/j.plipres.2024.101302_bb0225","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1158\/1055-9965.EPI-21-0669","article-title":"Association of endogenous pregnenolone, progesterone, and related metabolites with risk of endometrial and ovarian cancers in postmenopausal women: the B\u223cFIT cohort","volume":"30","author":"Trabert","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"5","key":"10.1016\/j.plipres.2024.101302_bb0230","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/carcin\/bgz127","article-title":"Reduced PAX2 expression in murine fallopian tube cells enhances estrogen receptor signaling","volume":"41","author":"Colina","year":"2020","journal-title":"Carcinogenesis"},{"issue":"1","key":"10.1016\/j.plipres.2024.101302_bb0235","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1210\/me.2009-0218","article-title":"BRCA1 regulates acetylation and ubiquitination of estrogen receptor-\u03b1","volume":"24","author":"Ma","year":"2010","journal-title":"Mol Endocrinol"},{"issue":"50","key":"10.1016\/j.plipres.2024.101302_bb0240","doi-asserted-by":"crossref","first-page":"31993","DOI":"10.1073\/pnas.2013595117","article-title":"Targeting progesterone signaling prevents metastatic ovarian cancer","volume":"117","author":"Kim","year":"2020","journal-title":"Proc Natl Acad Sci"},{"issue":"7","key":"10.1016\/j.plipres.2024.101302_bb0245","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1210\/clinem\/dgab195","article-title":"Progesterone receptors promote quiescence and ovarian cancer cell phenotypes via DREAM in p53-mutant fallopian tube models","volume":"106","author":"Mauro","year":"2021","journal-title":"J Clin Endocrinol Metabol"},{"issue":"11","key":"10.1016\/j.plipres.2024.101302_bb0250","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1016\/j.celrep.2017.02.049","article-title":"Progesterone prevents high-grade serous ovarian cancer by inducing necroptosis of p53-defective fallopian tube epithelial cells","volume":"18","author":"Wu","year":"2017","journal-title":"Cell Rep"},{"issue":"9","key":"10.1016\/j.plipres.2024.101302_bb0255","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1093\/humrep\/deaa177","article-title":"Fallopian tube epithelial cells express androgen receptor and have a distinct hormonal responsiveness when compared with endometrial epithelium","volume":"35","author":"Maclean","year":"2020","journal-title":"Hum Reprod"},{"issue":"9","key":"10.1016\/j.plipres.2024.101302_bb0260","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1093\/humrep\/deaa157","article-title":"Exposure of human fallopian tube epithelium to elevated testosterone results in alteration of cilia gene expression and beating","volume":"35","author":"Jackson-Bey","year":"2020","journal-title":"Hum Reprod"},{"issue":"4","key":"10.1016\/j.plipres.2024.101302_bb0265","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/modpathol.2016.219","article-title":"Steroid hormone synthesis by the ovarian stroma surrounding epithelial ovarian tumors: a potential mechanism in ovarian tumorigenesis","volume":"30","author":"Blanco","year":"2017","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.plipres.2024.101302_bb0270","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/IGC.0b013e3182788466","article-title":"Prognostic role of hormone receptors in ovarian cancer: a systematic review and meta-analysis","volume":"23","author":"Zhao","year":"2013","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"10.1016\/j.plipres.2024.101302_bb0275","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(13)70253-5","article-title":"Hormone-receptor expression and ovarian cancer survival: an ovarian tumor tissue analysis consortium study","volume":"14","author":"Sieh","year":"2013","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.plipres.2024.101302_bb0280","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20210478","article-title":"Expression of hormone receptors predicts survival and platinum sensitivity of high-grade serous ovarian cancer","volume":"41","author":"Tan","year":"2021","journal-title":"Biosci Rep"},{"issue":"21","key":"10.1016\/j.plipres.2024.101302_bb0285","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13215578","article-title":"Highly expressed progesterone receptor B isoform increases platinum sensitivity and survival of ovarian high-grade serous carcinoma","volume":"13","author":"Lin","year":"2021","journal-title":"Cancers"},{"issue":"19","key":"10.1016\/j.plipres.2024.101302_bb0290","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194588","article-title":"What\u2019s beyond BRCA mutational status in high grade serous ovarian cancer? The impact of hormone receptor expression in a large BRCA-profiled ovarian cancer patient series: a retrospective cohort study","volume":"14","author":"Perrone","year":"2022","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.plipres.2024.101302_bb0295","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1007\/s11845-021-02842-6","article-title":"The expression and clinical significance of ER\u03b2\/ER\u03b1 in ovarian cancer: can we predict the effectiveness of platinum plus taxane therapy?","volume":"191","author":"Bogush","year":"2022","journal-title":"Irish J Med Sci (1971)"},{"issue":"7","key":"10.1016\/j.plipres.2024.101302_bb0300","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.devcel.2022.02.017","article-title":"Cellular heterogeneity of human fallopian tubes in normal and hydrosalpinx disease states identified using scRNA-seq","volume":"57","author":"Ulrich","year":"2022","journal-title":"Dev Cell"},{"issue":"12","key":"10.1016\/j.plipres.2024.101302_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111838","article-title":"A molecular atlas of the human postmenopausal fallopian tube and ovary from single-cell RNA and ATAC sequencing","volume":"41","author":"Lengyel","year":"2022","journal-title":"Cell Rep"},{"issue":"8","key":"10.1016\/j.plipres.2024.101302_bb0310","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abm1831","article-title":"Longitudinal single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic ovarian cancer","volume":"8","author":"Zhang","year":"2022","journal-title":"Sci Adv"},{"issue":"2","key":"10.1016\/j.plipres.2024.101302_bb0315","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","article-title":"Dictionary learning for integrative, multimodal and scalable single-cell analysis","volume":"42","author":"Hao","year":"2024","journal-title":"Nat Biotechnol"},{"issue":"11","key":"10.1016\/j.plipres.2024.101302_bb0320","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14112583","article-title":"Model cell lines and tissues of different HGSOC subtypes differ in local estrogen biosynthesis","volume":"14","author":"Pavli\u010d","year":"2022","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.plipres.2024.101302_bb0325","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9124105","article-title":"AKR1C3 is associated with better survival of patients with endometrial carcinomas","volume":"9","author":"Hojnik","year":"2020","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.plipres.2024.101302_bb0330","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020279","article-title":"Metabolism of estrogens: turnover differs between platinum-sensitive and -resistant high-grade serous ovarian cancer cells","volume":"12","author":"Poschner","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.plipres.2024.101302_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117069","article-title":"Targeting estrogen metabolism in high-grade serous ovarian cancer shows promise to overcome platinum resistance","volume":"177","author":"Marolt","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.plipres.2024.101302_bb0340","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.mce.2006.12.006","article-title":"SDR-type human hydroxysteroid dehydrogenases involved in steroid hormone activation","volume":"265\u2013266","author":"Wu","year":"2007","journal-title":"Mol Cell Endocrinol"},{"issue":"4","key":"10.1016\/j.plipres.2024.101302_bb0345","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000485624","article-title":"The expression of HSD17B12 is associated with COX-2 expression and is increased in high-grade epithelial ovarian cancer","volume":"94","author":"Kemil\u00e4inen","year":"2018","journal-title":"Oncology"},{"issue":"1","key":"10.1016\/j.plipres.2024.101302_bb0350","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0039-128X(96)00174-2","article-title":"The key role of 17 beta-hydroxysteroid dehydrogenases in sex steroid biology","volume":"62","author":"Labrie","year":"1997","journal-title":"Steroids"},{"issue":"1","key":"10.1016\/j.plipres.2024.101302_bb0355","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41467-020-20675-2","article-title":"Crystal structure of steroid reductase SRD5A reveals conserved steroid reduction mechanism","volume":"12","author":"Han","year":"2021","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.plipres.2024.101302_bb0360","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3109\/03602532.2015.1011658","article-title":"Regioselective hydroxylation of steroid hormones by human cytochromes P450","volume":"47","author":"Niwa","year":"2015","journal-title":"Drug Metab Rev"},{"issue":"8","key":"10.1016\/j.plipres.2024.101302_bb0365","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1210\/en.2003-0192","article-title":"Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms","volume":"144","author":"Lee","year":"2003","journal-title":"Endocrinology"},{"issue":"27","key":"10.1016\/j.plipres.2024.101302_bb0370","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/oxfordjournals.jncimonographs.a024248","article-title":"Chapter 5: tissue-specific synthesis and oxidative metabolism of estrogens","volume":"2000","author":"Jefcoate","year":"2000","journal-title":"JNCI Monograph"},{"issue":"3","key":"10.1016\/j.plipres.2024.101302_bb0375","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1056\/NEJMra050776","article-title":"Estrogen carcinogenesis in breast cancer","volume":"354","author":"Yager James","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.plipres.2024.101302_bb0380","article-title":"Profiling the metabolome of uterine fluid for early detection of ovarian cancer","volume":"4","author":"Wang","year":"2023","journal-title":"Cell Rep Med"},{"issue":"20","key":"10.1016\/j.plipres.2024.101302_bb0385","doi-asserted-by":"crossref","first-page":"7369","DOI":"10.1158\/1078-0432.CCR-05-0466","article-title":"Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers","volume":"11","author":"Downie","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.plipres.2024.101302_bb0390","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1054\/bjoc.2001.1907","article-title":"Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer","volume":"85","author":"McFadyen","year":"2001","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.plipres.2024.101302_bb0395","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.18632\/oncotarget.1938","article-title":"Whole genome expression profiling of blood cells in ovarian cancer patients -prognostic impact of the CYP1B1, MTSS1, NCALD, and NOP14","volume":"5","author":"Isaksson","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.plipres.2024.101302_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2019.105439","article-title":"Human steroid biosynthesis, metabolism and excretion are differentially reflected by serum and urine steroid metabolomes: a comprehensive review","volume":"194","author":"Schiffer","year":"2019","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"41","key":"10.1016\/j.plipres.2024.101302_bb0405","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000012364","article-title":"Expression of resistance gene and prognosis of chemotherapy in primary epithelial ovarian cancer","volume":"97","author":"Yang","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.plipres.2024.101302_bb0410","first-page":"4262","article-title":"Multidrug resistance affects the prognosis of primary epithelial ovarian cancer","volume":"18","author":"Gao","year":"2019","journal-title":"Oncol Lett"},{"key":"10.1016\/j.plipres.2024.101302_bb0415","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s12885-015-1271-4","article-title":"High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma","volume":"15","author":"Cui","year":"2015","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.plipres.2024.101302_bb0420","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1210\/er.2015-1036","article-title":"The regulation of steroid action by sulfation and desulfation","volume":"36","author":"Mueller","year":"2015","journal-title":"Endocr Rev"},{"issue":"6","key":"10.1016\/j.plipres.2024.101302_bb0425","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.3892\/ol.2017.5969","article-title":"Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer","volume":"13","author":"Mungenast","year":"2017","journal-title":"Oncol Lett"},{"issue":"1","key":"10.1016\/j.plipres.2024.101302_bb0430","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ygyno.2008.08.037","article-title":"Estrone sulfatase activity in patients with advanced ovarian cancer","volume":"112","author":"Chura","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.plipres.2024.101302_bb0435","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13048-021-00840-x","article-title":"Simultaneous expression of steroid sulfatase and androgen receptor reduced overall survival of patients with epithelial ovarian tumors","volume":"14","author":"Calvillo-Robledo","year":"2021","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.plipres.2024.101302_bb0440","author":"Health"}],"container-title":["Progress in Lipid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163782724000353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163782724000353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T19:59:16Z","timestamp":1733687956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163782724000353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":88,"alternative-id":["S0163782724000353"],"URL":"https:\/\/doi.org\/10.1016\/j.plipres.2024.101302","relation":{},"ISSN":["0163-7827"],"issn-type":[{"value":"0163-7827","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From fallopian tube epithelium to high-grade serous ovarian cancer: A single-cell resolution review of sex steroid hormone signaling","name":"articletitle","label":"Article Title"},{"value":"Progress in Lipid Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.plipres.2024.101302","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101302"}}